Peramivir 150mg + Peramivir 300mg
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Peramivir 150mg + Peramivir 300mg
Peramivir 150mg + Peramivir 300mg is a phase 3 stage product being developed by BioCryst Pharmaceuticals for Influenza. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00486980. Target conditions include Influenza.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00486980 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Influenza